Heartflow (NASDAQ:HTFL) Upgraded at UBS Group

UBS Group upgraded shares of Heartflow (NASDAQ:HTFL) to a hold rating in a report released on Wednesday morning,Zacks reports.

HTFL has been the subject of several other research reports. Weiss Ratings raised Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Heartflow in a research note on Friday, August 14th. JPMorgan Chase & Co. boosted their price target on Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. Stifel Nicolaus lifted their target price on shares of Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Finally, Morgan Stanley boosted their target price on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.88.

Heartflow Trading Up 9.7%

Shares of HTFL opened at $49.88 on Wednesday. Heartflow has a 1-year low of $20.13 and a 1-year high of $51.78. The firm’s 50-day moving average price is $35.52 and its 200-day moving average price is $30.78. The firm has a market capitalization of $4.34 billion and a price-to-earnings ratio of -27.26.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business’s revenue was up 47.7% compared to the same quarter last year. On average, research analysts forecast that Heartflow will post -0.75 EPS for the current fiscal year.

Insider Transactions at Heartflow

In related news, CEO John Farquhar sold 27,230 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $50.00, for a total value of $1,361,500.00. Following the transaction, the chief executive officer directly owned 360,814 shares of the company’s stock, valued at approximately $18,040,700. This trade represents a 7.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Vikram Verghese sold 6,640 shares of Heartflow stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $50.03, for a total value of $332,199.20. Following the transaction, the chief financial officer owned 214,503 shares in the company, valued at $10,731,585.09. This trade represents a 3.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 208,765 shares of company stock worth $8,444,106 in the last three months. Corporate insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. TrueMark Investments LLC increased its holdings in Heartflow by 1.4% in the 1st quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock worth $654,000 after acquiring an additional 379 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow during the fourth quarter valued at approximately $27,000. Strs Ohio boosted its position in shares of Heartflow by 35.3% in the first quarter. Strs Ohio now owns 4,600 shares of the company’s stock worth $112,000 after purchasing an additional 1,200 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Heartflow in the fourth quarter worth $45,000. Finally, Legal & General Group Plc bought a new stake in shares of Heartflow during the 3rd quarter valued at $59,000.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).